<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4757">
  <stage>Registered</stage>
  <submitdate>18/12/2014</submitdate>
  <approvaldate>18/12/2014</approvaldate>
  <nctid>NCT02323126</nctid>
  <trial_identification>
    <studytitle>Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer</studytitle>
    <scientifictitle>A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym>EGF816</trialacronym>
    <secondaryid>2014-003731-20</secondaryid>
    <secondaryid>CEGF816X2201C</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - EGF816
Treatment: drugs - INC280
Treatment: drugs - Nivolumab

Experimental: Nivolumab and EGF816 - Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.

Experimental: Nivolumab and INC280 - Arm 2 (INC280 + nivolumab) is open and enrolling as planned.


Treatment: drugs: EGF816


Treatment: drugs: INC280


Treatment: drugs: Nivolumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) rate using RECIST version1.1</outcome>
      <timepoint>6 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with Adverse Events (AEs) - Safety of EGF816 and Nivolumab and INC280 and Nivolumab by looking at hematology and chemistry laboratory parameters, vital signs, and electrocardiograms (ECGs)</outcome>
      <timepoint>Continuously during study until 100 days after post study treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate (ORR)</outcome>
      <timepoint>baseline, every 8 weeks up to cycle 12, then every 12 weeks from cycle 13 until disease progression, consent withdrawal or death up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control rate</outcome>
      <timepoint>baseline, every 8 weeks upto cycle 12, then every 12 weeks from cycle 13 until disease progression, consent withdrawal or death up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>baseline, every 8 weeks upto cycle 12, then every 12 weeks from cycle 13 until disease progression, consent withdrawal or death up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>Start of treatment until death, average 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma pharmacokinetic parameters (AUClast, AUC0-t,AUCtau,Cmax, Tmax)</outcome>
      <timepoint>Cycle 1: Day1, Day 8, Day 15 and Cycle 2: Day 1, Cycle 4: Day 1 Cycle 6: Day 1 and Cycle 8: Day 1 Subsequent cycles (nivolumab only): every 8th cycle until discontinuation of study treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent must be obtained prior to any screening procedures

          -  Presence of at least one measurable lesion according to RECIST v.1.1

          -  ECOG performance status = 2

          -  Patients with histologically documented locally advanced, recurrent and/or metastatic
             NSCLC

          -  Tumor tissue for determination and/or confirmation of genetic pre-requisites (i.e.
             EGFR T790M positivity post progression on EGFR TKI for Group 1; cMet status for Group
             2) must be provided for analysis

        Group 1 patients:

          -  Patients with EGFR T790M NSCLC (adenocarcinoma)

          -  Documented progression of disease according to RECIST v1.1 following primary standard
             of care (e.g. erlotinib, gefitinib)

        Group 2 patients:

          -  Patients with EGFR wild-type NSCLC

          -  Documented progression of disease according to RECIST v1.1 following standard of care
             (e.g. platinum doublet).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients who have received more than one prior line of EGFR TKI therapy1 (applies only
             to Group 1)

          -  Previous treatment with a c-MET inhibitor or HGF-targeting therapy (applies only to
             Group 2)

          -  Patients with brain metastases. However, if radiation therapy and/or surgery has been
             completed and serial evaluation by CT (with contrast enhancement) or MRI over a
             minimum of one month demonstrates the disease to be stable and if the patient remains
             must have no need for treatment with steroids

          -  Patients who require emergent use of systemic steroids, chronic use of prednisone
             (greater than 10mg or an equivalent steroid dose daily) or emergent surgery and/or
             radiotherapy.

          -  History of allergy or hypersensitivity to nivolumab components

          -  Patients with any known or suspected, current or past history of, autoimmune disease.
             Patients with type I diabetes mellitus, hypothyroidism only requiring hormone
             replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring
             systemic treatment, or conditions not expected to recur in the absence of an external
             trigger are permitted to enroll

          -  Patients with a condition requiring chronic systemic treatment with either
             corticosteroids(&gt; 10 mg daily prednisone equivalent) or other immunosuppressive
             medications within 14 days of treatment start. Inhaled or topical steroids, and
             adrenal replacement steroid doses&gt; 10 mg daily prednisone equivalent, are permitted in
             the absence of active autoimmune disease

          -  Known history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS)

          -  Any positive test for hepatitis B virus or hepatitis C virus indicating acute or
             chronic infection

          -  Patients with interstitial lung disease that is symptomatic or may interfere with the
             detection or management of suspected drug-related pulmonary toxicity

          -  Patients with interstitial lung disease that is symptomatic or may interfere with the
             detection or management of suspected drug-related pulmonary toxicity

        Prior therapy:

          -  Patients who have been treated with prior PD-1 and PD-L1 agents

          -  Patients who previously received agents targeting c-MET and/or EGFR T790M Note:
             Previous treatment with afatinib may be allowable after discussions between Novartis
             and Investigator.

          -  Patients with the following laboratory abnormalities:

               -  Absolute Neutrophil Count (ANC) &lt;1.5 x 109/L

               -  Hemoglobin (Hgb) &lt;9 g/dL

               -  Platelets &lt;100 x 109/L

               -  Total bilirubin &gt;1.5 x upper limit of normal (ULN). For patients with Gilbert's
                  syndrome total bilirubin &gt;2.5 x upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt;3 x ULN

               -  Serum creatinine &gt;1.5 x ULN and/or measured or calculated creatinine clearance
                  &lt;75% LLN

               -  For patients being screened for Group 2, asymptomatic serum amylase &gt; CTCAE Grade
                  2 (1.5-2.0 x ULN). Patients with Grade 1 or Grade 2 serum amylase at the
                  beginning of the study must be confirmed to have no signs or symptoms suggesting
                  pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging
                  findings of pancreas, etc.)

               -  For patients being screened for Group 2: Serum lipase &gt; ULN

          -  Female patients who are either pregnant or nursing.

          -  Women of child bearing potential who refuse or are not able to use a highly effective
             method of contraception as defined in the study protocol.

          -  Sexually active males unless they use a condom during intercourse while taking drug
             and for 31 weeks after the last dose of study treatment.

        Other protocol-related inclusion/exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>9/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>68</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>10/04/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital>Novartis Investigative Site - Camperdown</hospital>
    <hospital>Novartis Investigative Site - Chermside</hospital>
    <hospital>Novartis Investigative Site - Adelaide</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Tronche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wurzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PN</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Comunidad Valenciana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Chur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Gen√®ve</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine the efficacy and safety of Nivolumab in combination with EGF816 and of Nivolumab
      in combination with INC280 in previously treated NSCLC patients</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02323126</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address />
      <phone>1-888-669-6682</phone>
      <fax />
      <email>Novartis.email@novartis.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>